WHAT IS THE BENEFIT OF DENOSUMAB (XGEVA^®) IN PATIENT WITH SOLID TUMOURS WITH BONE METASTASES?

Česká verzia

Authors: D. Pacík
Published in the journal: Urol List 2013; 11(3): 22-24

Summary

Prostate cancer, renal cell carcinoma and bladder cancer often metastasize to bone. Untill recently bisphosphonates (BP) were drug of choice in these patients, with various efficacy, indications, mode of administration and toxicity profile. Denosumab is a novel human monoclonal antibody now available for the treatment of cancer induced bone disease with a different mode of action, safety profile and administration. Denosumab was superior in head to head comparisons to zoledronic acid in preventing or delaying first SRE in prostate cancer and breast cancer patients as well as in patients suffering from other solid tumors. Favourable toxicity profile enables administration of denosumab even in patients excluded for bisphosponates use or in patients where dose reductions of BP were necessary.

Key words:
prostate cancer, skeletal related events, denosumab, pain, quality of life

Zdroje

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategie. Cancer Treat Rev 2001; 27: 165–176.

2. Saad F, Chen YM, Gleason DM et al. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007; 5: 390–396.

3. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879–82.

4. Pacík D. Význam inhibice ligandu RANK v léčbě kostních komplikací u pacientů s metastazujícím karcinomem prostaty. Urol List 2010; 8: 58–61.

5. Lipton A, Fizazi K, Stopeck AT et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082–92.

6. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28(35): 5132–5139.

7. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813–822.

8. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125–1132.

9. Henry D, von Moos R, Hungria V, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer. An analysis of solid tumors. Presentation at: American Society of Clinical Oncology Annual Meeting. June 4–8, 2010; Chicago, Illinois.

10. Scagliotti GV, Hirsh V, Siena S et al. Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study. J Thorac Oncol 2012; 7: 1823–1829.

11. Smith HS. Painful Osseous Metastase. Pain Physician 2011; 14: E373–E405.

12. Brown JE, Cleeland C, Fallowfield L et al. Pain outcomes in patients with bone metastases from castrate-resistant prostate cancer: Results from a phase 3 trial of denosumab vs zoledronic acid. European Association of Urologists 2011: abstract 1091 and poster presentation.

13. Cleeland CS, Patrick DL, Fallowfield L et al. Effects of denosumab vs zoledronic acid on pain in patients with advanced cancer and bone metastases: An integrated analysis of 3 pivotal trials. European Cancer Organisation 2010: abstract 1248P and poster presentation.

14. Fizazi K, Brown JE, Carducci M et al. Denosumab in Patients with Metastatic Prostate Cancer Previously Treated with Denosumab or Zoledronic Acid: 2-year Open-label Extension Phase Results from the Pivotal Phase 3 Study. European Society for Medical Oncology 2012: abstract 937P and poster presentation.